GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » EV-to-Revenue

Vicore Pharma Holding AB (OSTO:VICO BTA) EV-to-Revenue : -159.77 (As of Jul. 14, 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vicore Pharma Holding AB's enterprise value is kr-957.81 Mil. Vicore Pharma Holding AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr6.00 Mil. Therefore, Vicore Pharma Holding AB's EV-to-Revenue for today is -159.77.

The historical rank and industry rank for Vicore Pharma Holding AB's EV-to-Revenue or its related term are showing as below:

OSTO:VICO BTA' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.2   Med: 1650.34   Max: 39475
Current: 254.12

During the past 12 years, the highest EV-to-Revenue of Vicore Pharma Holding AB was 39475.00. The lowest was 3.20. And the median was 1650.34.

OSTO:VICO BTA's EV-to-Revenue is ranked worse than
90.44% of 994 companies
in the Biotechnology industry
Industry Median: 8.23 vs OSTO:VICO BTA: 254.12

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-14), Vicore Pharma Holding AB's stock price is kr8.00. Vicore Pharma Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.53. Therefore, Vicore Pharma Holding AB's PS Ratio for today is 15.18.


Vicore Pharma Holding AB EV-to-Revenue Historical Data

The historical data trend for Vicore Pharma Holding AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB EV-to-Revenue Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 7.56

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.82 18.46 4.29 7.56 100.92

Competitive Comparison of Vicore Pharma Holding AB's EV-to-Revenue

For the Biotechnology subindustry, Vicore Pharma Holding AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's EV-to-Revenue falls into.


;
;

Vicore Pharma Holding AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vicore Pharma Holding AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-957.812/5.995
=-159.77

Vicore Pharma Holding AB's current Enterprise Value is kr-957.81 Mil.
Vicore Pharma Holding AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vicore Pharma Holding AB  (OSTO:VICO BTA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vicore Pharma Holding AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=8.00/0.527
=15.18

Vicore Pharma Holding AB's share price for today is kr8.00.
Vicore Pharma Holding AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.53.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vicore Pharma Holding AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines